You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarbetocin
Accession NumberDB01282
TypeSmall Molecule
GroupsApproved
DescriptionCarbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.
Structure
Thumb
Synonyms
1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin
1-Butyric acid-2-(3-(P-methoxyphenyl)-L-alanine)oxytocin
Carbetocino
Carbetocinum
Deamino-2-O-methyltyrosine-1-carbaoxytocin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Duratocin InjectionLiquid100 mcgIntravenousFerring Inc1999-08-01Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII88TWF8015Y
CAS number37025-55-1
WeightAverage: 988.161
Monoisotopic: 987.484787417
Chemical FormulaC45H69N11O12S
InChI KeyNSTRIRCPWQHTIA-DTRKZRJBSA-N
InChI
InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1
IUPAC Name
(2S)-2-{[(2S)-1-[(3R,6S,9S,12S,15S)-12-[(2S)-butan-2-yl]-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosane-3-carbonyl]pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-4-methylpentanamide
SMILES
[H][C@]1(NC(=O)[[email protected]](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[[email protected]](NC(=O)[[email protected]](CC(N)=O)NC(=O)[[email protected]](CCC(N)=O)NC1=O)C(=O)N1CCC[[email protected]]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC
Pharmacology
IndicationUsed to control postpartum hemorrhage and bleeding after giving birth.
Structured Indications
PharmacodynamicsCarbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is sold under the trade name Duratocin. It is an analogue of oxytocin, and its action is similar to that of oxytocin; it causes contraction of the uterus.
Mechanism of actionCarbetocin binds to oxytocin receptors present on the smooth musculature of the uterus, resulting in rhythmic contractions of the uterus, increased frequency of existing contractions, and increased uterine tone. The oxytocin receptor content of the uterus is very low in the non-pregnant state, and increases during pregnancy, reaching a peak at the time of delivery.
TargetKindPharmacological actionActionsOrganismUniProt ID
Oxytocin receptorProteinyes
agonist
HumanP30559 details
Related Articles
AbsorptionBioavailability is 80% following intramuscular injection.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life40 minutes
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Carbetocin.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carbetocin.Approved
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Carbetocin.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Carbetocin.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Carbetocin.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Carbetocin.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Carbetocin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Carbetocin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Carbetocin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Carbetocin.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Carbetocin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Carbetocin.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Carbetocin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Carbetocin.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Carbetocin.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Carbetocin.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Carbetocin.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Carbetocin.Experimental
BarbitalBarbital may increase the hypotensive activities of Carbetocin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Carbetocin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Carbetocin.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carbetocin.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Carbetocin.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Carbetocin.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Carbetocin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Carbetocin.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Carbetocin.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Carbetocin.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Carbetocin.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Carbetocin.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbetocin.Approved, Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Carbetocin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Carbetocin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Carbetocin.Approved
Carboprost TromethamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Carbetocin.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Carbetocin.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbetocin.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carbetocin.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Carbetocin.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Carbetocin.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Carbetocin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Conivaptan.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Carbetocin.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carbetocin.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Carbetocin.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Carbetocin.Approved
DinoprostoneThe risk or severity of adverse effects can be increased when Dinoprostone is combined with Carbetocin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Carbetocin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Carbetocin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Carbetocin.Approved
DuloxetineCarbetocin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Carbetocin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Carbetocin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Carbetocin is combined with Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Carbetocin.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Carbetocin is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carbetocin.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Carbetocin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Carbetocin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Carbetocin.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fimasartan.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Carbetocin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Carbetocin.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Carbetocin.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Carbetocin.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Carbetocin.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carbetocin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Hydroflumethiazide.Approved
IloprostThe risk or severity of adverse effects can be increased when Carbetocin is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Carbetocin.Approved
IndoraminThe risk or severity of adverse effects can be increased when Carbetocin is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Carbetocin.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Carbetocin.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Carbetocin.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Carbetocin.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Carbetocin.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Carbetocin.Approved
LacidipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Carbetocin.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Levobupivacaine.Approved
LevodopaCarbetocin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Carbetocin.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Carbetocin.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Carbetocin.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Carbetocin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Carbetocin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Carbetocin.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbetocin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Carbetocin.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Carbetocin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Carbetocin.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Carbetocin.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Carbetocin.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Carbetocin.Approved
MisoprostolThe risk or severity of adverse effects can be increased when Misoprostol is combined with Carbetocin.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Carbetocin.Approved
MorphineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Carbetocin.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Carbetocin.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Carbetocin.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Carbetocin.Approved
NicorandilNicorandil may increase the hypotensive activities of Carbetocin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Carbetocin.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Carbetocin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Carbetocin.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Carbetocin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Carbetocin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Carbetocin is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carbetocin.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Carbetocin is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Carbetocin.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Carbetocin.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Carbetocin.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Carbetocin.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Carbetocin.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Phentolamine.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Carbetocin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Pipamperone.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Carbetocin is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Carbetocin.Approved
PrimidonePrimidone may increase the hypotensive activities of Carbetocin.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Carbetocin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Carbetocin.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carbetocin.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Carbetocin.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Carbetocin.Approved
RasagilineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Carbetocin.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Carbetocin.Approved
RisperidoneCarbetocin may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Carbetocin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sacubitril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Carbetocin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Carbetocin.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Carbetocin.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Carbetocin is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sufentanil.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carbetocin.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Carbetocin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Carbetocin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Carbetocin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Thioridazine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Carbetocin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Carbetocin.Approved
TolazolineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Carbetocin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Carbetocin.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Carbetocin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Carbetocin.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Carbetocin.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesH01BB03
AHFS Codes
  • 76:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9806
Blood Brain Barrier-0.9678
Caco-2 permeable-0.774
P-glycoprotein substrateSubstrate0.8748
P-glycoprotein inhibitor IInhibitor0.5541
P-glycoprotein inhibitor IINon-inhibitor0.8748
Renal organic cation transporterNon-inhibitor0.8938
CYP450 2C9 substrateNon-substrate0.8785
CYP450 2D6 substrateNon-substrate0.7363
CYP450 3A4 substrateSubstrate0.6535
CYP450 1A2 substrateNon-inhibitor0.8997
CYP450 2C9 inhibitorNon-inhibitor0.7966
CYP450 2D6 inhibitorNon-inhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.7442
CYP450 3A4 inhibitorNon-inhibitor0.8166
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9196
Ames testNon AMES toxic0.8318
CarcinogenicityNon-carcinogens0.8517
BiodegradationNot ready biodegradable0.9703
Rat acute toxicity3.2094 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9403
hERG inhibition (predictor II)Inhibitor0.6577
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
LiquidIntravenous100 mcg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0265 mg/mLALOGPS
logP0.14ALOGPS
logP-3.6ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)11.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count10ChemAxon
Polar Surface Area362.51 Å2ChemAxon
Rotatable Bond Count18ChemAxon
Refractivity250.18 m3·mol-1ChemAxon
Polarizability101 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentCyclic peptides
Alternative Parents
Substituents
  • Cyclic alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • Macrolactam
  • Alpha-amino acid amide
  • N-substituted-alpha-amino acid
  • Methoxybenzene
  • Pyrrolidine-2-carboxamide
  • Pyrrolidine carboxylic acid or derivatives
  • Phenol ether
  • N-acylpyrrolidine
  • Anisole
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Cyclic alcohol
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Primary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Dialkylthioether
  • Thioether
  • Ether
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for oxytocin. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
OXTR
Uniprot ID:
P30559
Molecular Weight:
42770.99 Da
References
  1. Engstrom T, Barth T, Melin P, Vilhardt H: Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol. 1998 Aug 21;355(2-3):203-10. [PubMed:9760035 ]
  2. Gimpl G, Postina R, Fahrenholz F, Reinheimer T: Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. Eur J Pharmacol. 2005 Mar 7;510(1-2):9-16. [PubMed:15740719 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on May 17, 2007 10:46 / Updated on August 17, 2016 12:23